What class of drug is sirolimus?
Sirolimus (also known as rapamycin) is an immunosuppressant. It belongs to the class of drugs called mTOR inhibitors (mechanistic target of rapamycin inhibitors). These drugs suppress immune-cell signaling pathways that control cell growth and immune responses.
What does sirolimus treat?
Sirolimus is used to prevent organ rejection in transplant patients and is also used in certain cancer and skin-related contexts where blocking mTOR-dependent cell growth is helpful, depending on the specific product and indication.
How is sirolimus different from tacrolimus or cyclosporine?
Sirolimus is not a calcineurin inhibitor. Tacrolimus and cyclosporine work by blocking calcineurin, which reduces T-cell activation through different signaling steps. Sirolimus works further downstream by inhibiting mTOR, so it has a different mechanism and side-effect profile than calcineurin inhibitors.
What side effects are commonly linked to mTOR inhibitors like sirolimus?
Commonly discussed risks with sirolimus therapy include infections (from immune suppression), mouth ulcers, high blood lipids, fluid buildup (edema), and effects on blood counts. The exact risk pattern varies by dose, other immunosuppressants used with it, and patient factors.
Patents and drug information lookup
For additional drug-specific background (including regulatory and market-related details that may vary by formulation), DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/